CN102159184B - 含有对乙酰氨基酚的液体药物制剂 - Google Patents

含有对乙酰氨基酚的液体药物制剂 Download PDF

Info

Publication number
CN102159184B
CN102159184B CN2009801367138A CN200980136713A CN102159184B CN 102159184 B CN102159184 B CN 102159184B CN 2009801367138 A CN2009801367138 A CN 2009801367138A CN 200980136713 A CN200980136713 A CN 200980136713A CN 102159184 B CN102159184 B CN 102159184B
Authority
CN
China
Prior art keywords
pharmaceutical preparation
respect
amount
cumulative volume
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801367138A
Other languages
English (en)
Chinese (zh)
Other versions
CN102159184A (zh
Inventor
F·马里奥蒂
P·斯卡尔佩蒂
L·拉尼
M·瓦伦蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CN102159184A publication Critical patent/CN102159184A/zh
Application granted granted Critical
Publication of CN102159184B publication Critical patent/CN102159184B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801367138A 2008-10-09 2009-09-28 含有对乙酰氨基酚的液体药物制剂 Expired - Fee Related CN102159184B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425654 2008-10-09
EP08425654.4 2008-10-09
PCT/EP2009/062501 WO2010040652A1 (en) 2008-10-09 2009-09-28 Liquid pharmaceutical formulation containing paracetamol

Publications (2)

Publication Number Publication Date
CN102159184A CN102159184A (zh) 2011-08-17
CN102159184B true CN102159184B (zh) 2013-09-04

Family

ID=40282272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801367138A Expired - Fee Related CN102159184B (zh) 2008-10-09 2009-09-28 含有对乙酰氨基酚的液体药物制剂

Country Status (14)

Country Link
US (1) US20120115958A1 (enExample)
EP (1) EP2349207B1 (enExample)
JP (1) JP2012505172A (enExample)
KR (1) KR20110067103A (enExample)
CN (1) CN102159184B (enExample)
AR (1) AR073793A1 (enExample)
AU (1) AU2009301296A1 (enExample)
BR (1) BRPI0919796A2 (enExample)
CA (1) CA2737391A1 (enExample)
EA (1) EA018401B1 (enExample)
GE (1) GEP20135723B (enExample)
MX (1) MX2011003695A (enExample)
UA (1) UA103906C2 (enExample)
WO (1) WO2010040652A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
PH12017501005B1 (en) * 2014-12-20 2024-03-27 Troikaa Pharmaceuticals Ltd Injectable formulations of paracetamol
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
CA3032996C (en) 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
TWI620577B (zh) * 2016-11-23 2018-04-11 乙醯胺酚及曲馬多共溶複方止痛口服液
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
CN110115708A (zh) * 2018-02-07 2019-08-13 保瑞药业股份有限公司 乙酰胺酚及曲马多共溶复方止痛口服液
GR1009630B (el) 2018-03-14 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη και ακεταμινοφαινη
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
NL2024161B1 (en) * 2019-11-05 2021-07-20 Mperium B V Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
AU2023277704A1 (en) * 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
ES3034164T3 (en) 2022-11-08 2025-08-13 Laboratorios Ern S A Paracetamol oral solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047502A1 (en) * 2001-12-07 2003-06-12 Santos Ma Joyce Bedelia B Taste masked aqueous liquid pharmaceutical composition
US20080085892A1 (en) * 2006-08-31 2008-04-10 Sangeetha Kandeepan Liquid dosage form of acetaminophen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047502A1 (en) * 2001-12-07 2003-06-12 Santos Ma Joyce Bedelia B Taste masked aqueous liquid pharmaceutical composition
US20080085892A1 (en) * 2006-08-31 2008-04-10 Sangeetha Kandeepan Liquid dosage form of acetaminophen

Also Published As

Publication number Publication date
UA103906C2 (ru) 2013-12-10
AU2009301296A1 (en) 2010-04-15
WO2010040652A1 (en) 2010-04-15
CA2737391A1 (en) 2010-04-15
EA018401B1 (ru) 2013-07-30
CN102159184A (zh) 2011-08-17
EA201170543A1 (ru) 2011-10-31
KR20110067103A (ko) 2011-06-21
MX2011003695A (es) 2011-08-17
BRPI0919796A2 (pt) 2015-12-15
US20120115958A1 (en) 2012-05-10
GEP20135723B (en) 2013-01-10
AR073793A1 (es) 2010-12-01
EP2349207B1 (en) 2015-05-13
EP2349207A1 (en) 2011-08-03
JP2012505172A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
CN102159184B (zh) 含有对乙酰氨基酚的液体药物制剂
US11406712B2 (en) Phenylephrine-containing liquid formulations
US7101572B2 (en) Taste masked aqueous liquid pharmaceutical composition
EP1438026B1 (en) Taste masking spill-resistant formulation
MXPA06013481A (es) Composicion de suspension farmaceutica.
EA022751B1 (ru) Жидкая композиция деферипрона с замаскированным вкусом
US20250090669A1 (en) Pharmaceutical syrup formulation or suspension
JP5611672B2 (ja) 経口ゼリー剤
WO2019174755A1 (en) Oral solutions comprising tramadol and acetaminophen
US20060198856A1 (en) Ibuprofen suspension stabilized with docusate sodium
NL2024160B1 (en) Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
EP4279062A1 (en) Liquid composition and its use, treatment method and kit
HK1123993A (en) Phenylephrine-containing liquid formulations
HK1123993B (en) Phenylephrine-containing liquid formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130904

Termination date: 20150928

EXPY Termination of patent right or utility model